Kiwi Biosciences
Patent-pending enzymes to break down common dietary triggers
What they do
People with Irritable Bowel Syndrome experience digestive distress after eating common dietary trigger foods.
The company develops patent-pending enzymes that break down common digestive triggers in food to reduce IBS symptoms.
Consumers with IBS and related digestive sensitivities who want to tolerate normal meals.
Founders
Interdisciplinary thinker: scientifically-minded; humanist at heart Joint concentration in physics and comparative literature (Harvard 2017), now submerging myself into the intricate world of biology. I've struggled with chronic gut issues for most of my adult life, which led me to developing the current formulation of FODZYME and launching Kiwi Biosciences.
Formerly co-founder and CEO at auggi.ai, a digital gut health coach for patients with Irritable Bowel Syndrome (IBS). auggi was recently acquired by Seed Health. Completed my MPH in Epidemiology at the Harvard School of Public Health and a Master's in Computer and Information Science at Cornell University.
Company timeline
- Founded2020
- YC batchSummer 2021
- StatusActive
- Team size10 people
- LocationBoston, MA, USA
Similar startups
